<DOC>
	<DOCNO>NCT01181128</DOCNO>
	<brief_summary>The primary objective study : evaluate safety tolerability rFVIIIFc administer prophylaxis ( Arm 1 ) , weekly ( Arm 2 ) , on-demand ( Arm 3 ) , surgical treatment regimen ; evaluate efficacy rFVIIIFc tailor prophylaxis regimen ( Arm 1 ) ; evaluate efficacy rFVIIIFc administer on-demand ( Arm 3 ) surgical treatment regimen . The secondary objective study : characterize PK profile rFVIIIFc compare PK rFVIIIFc currently market product , Advate® ; characterize range dose schedule require adequately prevent bleed prophylaxis regimen , maintain hemostasis surgical setting , treat bleed episode on-demand , weekly treatment , prophylaxis setting .</brief_summary>
	<brief_title>Study Evaluate Safety , Pharmacokinetics Efficacy Recombinant Factor VIII Fc Fusion Protein ( rFVIIIFc ) Previously Treated Subjects With Severe Hemophilia A</brief_title>
	<detailed_description>Participants assign one three treatment regimen : 1 ) tailor prophylaxis regimen , 2 ) weekly dose regimen , 3 ) on-demand regimen . Treatment continue 28 ( ±2 ) 52 ( ±2 ) week . PK assessments participant conduct vary schedule , accord participant ' group assignment . Additionally , two subgroup define . One subgroup participant undergo PK profile single dose comparator Advate® . A second subgroup consist participant treatment arm require surgery study . Depending upon country location , participant might option continue treatment within study 8HA01EXT ( NCT01454739 ) .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Male , ≥12 year age weight least 40 kg Diagnosed severe hemophilia A , define &lt; 1 IU/dL ( &lt; 1 % ) endogenous Factor VIII ) History least 150 documented prior exposure day Factor VIII product Platelet count ≥100,000 cells/μL History Factor VIII inhibitor Kidney liver dysfunction Diagnosed coagulation disorder ( ) addition hemophilia A Prior history hypersensitivity anaphylaxis associate FVIII IV immunoglobulin administration</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>